Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Pancreatic Cancer Vaccine in advanced pancreatic cancer
NCT03329248Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Nov 2017
- Primary completion
- Aug 2018
- Modality
- Gene Editing, Vaccines & Immunotherapeutics, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, ETBX-011, GI-4000, haNK in pancreatic cancer (PC), sponsored by ImmunityBio, Inc.. Started Nov 2017; status: terminated.
02
Drugs
nogapendekin alfa inbakiceptETBX-011GI-4000haNK
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03329248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329248.